ClinicalTrials.gg
CompletedNCT04408794Updated May 18, 2023Results posted

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

A Phase 2/3 interventional study of Zavegepant (BHV-3500) in Acute Migraine, sponsored by Pfizer. Completed at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
974
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.

Enrollment
5th of 12
974 · median 225
Started
2020
with 1 other
Phase 2/3
3 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 2/3, and was the 2nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About zavegepant

zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing zavegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine.

* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.

03

Conditions studied

  • Acute Migraine

Keywords

  • migraine, headache, intranasal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2-8 moderate to severe migraines/month within the last 3 months
  • Migraine attacks present for more than 1 year with age of onset of migraines prior to 50 years of age
  • Migraine attacks, on average, lasting about 4-72 hours if untreated
  • Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the screening visit
  • Ability to distinguish migraine attacks from tension/cluster headaches
  • Participants with for use of triptans may be included provided they meet all other study entry criteria

Exclusion criteria

Exclusion Criteria:

  • History of disease
  • History of basilar or hemiplegic migraine
  • Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder
  • History of nasal surgery in the 6 months preceding the screening visit
  • History of gallstones or cholecystectomy
  • History of gastric, or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric balloon, etcetera), or other disease or condition (for example, chronic pancreatitis, ulcerative colitis, etcetera) that causes malabsorption.
  • ≥ 33
  • ≥6.5%
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
974 participants (actual)

Study arms

  • Experimental
    Zavegepant (BHV-3500)

    10 mg intranasal (IN) up to 8 times per month, up to 1 year

    Drug: Zavegepant (BHV-3500)

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation

    An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in participants or clinical investigation participants administered an investigational (medicinal) product that does not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received study drug; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the other serious outcomes.

    Time frame: From study drug dosing up to the end of the study (up to 52 weeks)

  2. Number Of Participants With Clinically Significant Laboratory Abnormalities

    Clinically significant laboratory abnormalities were defined as Grades 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome. Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, low-density lipoprotein (LDL)-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in to be included for a given parameter. Laboratory results were presented in US units.

    Time frame: From study drug dosing up to the end of the study (up to 52 weeks)

07

Results

Posted Mar 16, 2023

Participant flow

The study was conducted at 63 sites in the United States.

Participant flow — Overall Study
MilestoneZavegepant 10 mg
Started608
Treated/safety analysis set603
Completed341
Not completed267
Withdrew: Adverse event43
Withdrew: Infrequent study drug usage43
Withdrew: Lack of efficacy61
Withdrew: Lost to follow-up33
Withdrew: Non-compliance6
Withdrew: Physician decision1
Withdrew: Pregnancy6
Withdrew: Protocol deviation9
Withdrew: Sheehan-sts result1
Withdrew: Withdrawal by subject57
Withdrew: Terminated study prematurely due to covid-19 - adverse event2
Withdrew: Never treated migraine5

Outcome measures

PrimaryNumber Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation

An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in participants or clinical investigation participants administered an investigational (medicinal) product that does not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received study drug; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the other serious outcomes.

Time frame:
From study drug dosing up to the end of the study (up to 52 weeks)
Reported as:
Number · Participants
Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation
ParticipantsZavegepant 10 mg
AEs460
SAEs7
AEs leading to discontinuation41
PrimaryNumber Of Participants With Clinically Significant Laboratory Abnormalities

Clinically significant laboratory abnormalities were defined as Grades 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome. Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, low-density lipoprotein (LDL)-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in to be included for a given parameter. Laboratory results were presented in US units.

Time frame:
From study drug dosing up to the end of the study (up to 52 weeks)
Reported as:
Number · Participants
Number Of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsZavegepant 10 mg
Alanine Aminotransferase3
Aspartate Aminotransferase5
Albumin0
Alkaline Phosphatase0
Bicarbonate0
Biliburin0
Calcium, low0
Calcium, high0
Cholesterol0
Creatine Kinase (All Methods)13
Creatine Kinase13
Creatinine0
Glomerular Filtration Rate, Estimated0
LDL-cholesterol21
LDL-cholesterol, fasting6
LDL-cholesterol, not fasting15
Lactate Dehydrogenase0
Potassium, low0
Potassium, high1
Sodium, low0
Sodium, high0
Triglycerides1
Triglycerides, fasting0
Triglycerides, not fasting1
Uric Acid0
Eosinophils0
Hemoglobin0
Lymphocytes, low0
Lymphocytes, high0
Neutrophils2
Platelets0
White Blood Cells0
Qualitative Glucose0
Qualitative Protein0
Urine Erythrocytes0

Adverse events

Collected over From study drug dosing up to the end of the study (up to 52 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant 10 mg0/603 (0%)7/603 (1.2%)336/603 (55.7%)
Most frequent serious events
Most frequent serious events
EventZavegepant 10 mg
AppendicitisInfections and infestations1/603
Herpes zoster meningoencephalitisInfections and infestations1/603
PneumoniaInfections and infestations1/603
Bile duct stenosisHepatobiliary disorders1/603
ConcussionInjury, poisoning and procedural complications1/603
FallInjury, poisoning and procedural complications1/603
Back painMusculoskeletal and connective tissue disorders1/603
Multiple sclerosisNervous system disorders1/603
PleurisyRespiratory, thoracic and mediastinal disorders1/603
Most frequent other events
Most frequent other events
EventZavegepant 10 mg
DysgeusiaNervous system disorders236/603
Nasal discomfortRespiratory, thoracic and mediastinal disorders62/603
COVID-19Infections and infestations45/603
NauseaGastrointestinal disorders37/603
Nasal congestionRespiratory, thoracic and mediastinal disorders33/603
Throat irritationRespiratory, thoracic and mediastinal disorders33/603
Back painMusculoskeletal and connective tissue disorders33/603

Baseline characteristics

Safety analysis set included participants in the enrolled analysis set who took the study drug, that is, non-missing study drug start date/time.

Age, Continuous
Age, Continuous(years)Zavegepant 10 mg
Mean42.1 ± 12.46
Sex: Female, Male
Sex: Female, Male(Participants)Zavegepant 10 mg
Female517
Male86
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zavegepant 10 mg
Hispanic or Latino71
Not Hispanic or Latino532
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zavegepant 10 mg
American Indian or Alaska Native2
Asian23
Native Hawaiian or Other Pacific Islander2
Black or African American70
White502
More than one race4
Unknown or Not Reported0
08

Study locations

67 sites
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Coastal Clinical Research, LLC, An AMR Co.
    Mobile, Alabama 36608, United States
  • Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Wr-Pri, Llc
    Newport Beach, California 92660, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • CT Clinical Research
    Cromwell, Connecticut 06416, United States
  • Ki Health Partners, LLC dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32819, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Northwest Clinical Trials Inc.
    Boise, Idaho 83704, United States
  • Community Hospital of Anderson and Madison County Inc
    Anderson, Indiana 46011, United States
  • Fort Wayne Neurological Center
    Fort Wayne, Indiana 46804, United States
  • Collective Medical Research
    Prairie Village, Kansas 66208, United States
  • Crescent City Headache and Neurology Center
    Chalmette, Louisiana 70043, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Community Clinical Research Network
    Marlborough, Massachusetts 01752, United States
  • Boston Neuro Research Center
    South Dartmouth, Massachusetts 02747, United States
  • Medvadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • Michigan Headache and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Dartmouth-Hitchcock Heater Road
    Lebanon, New Hampshire 03766, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Montefiore Medical Center: Headache Center
    Bronx, New York 10461, United States
  • Regional Clinical Research
    Endwell, New York 13760, United States
  • Fieve Clinical Research, Inc
    New York, New York 10017, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • PharmQuest LLC
    Greensboro, North Carolina 27408, United States
  • Wilmington Health, PLLC
    Wilmington, North Carolina 28401, United States
  • OK Clinical Research LLC
    Edmond, Oklahoma 73034, United States
  • Tekton Research, Inc.
    Yukon, Oklahoma 73099, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians, Inc.
    Union, Pennsylvania 15401, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Red Star Research LLC
    Lake Jackson, Texas 77566, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Seattle Women's: Health, Research, Gynecology
    Seattle, Washington 98105, United States
  • Clinical Investigation Specialist, Inc.
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Dec 2021, 17 months.

Results were first posted in Mar 2023, 1 year 3 months after primary completion. A results delay was requested in Sep 2022.

Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
May 29, 2020
StartActual
Jun 29, 2020
Primary completionActual
Dec 9, 2021
CompletionActual
Dec 23, 2021
Results delay requested
Sep 25, 2022
Results first posted
Mar 16, 2023
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04408794
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 29, 2020
Start date
Jun 29, 2020
Primary completion
Dec 9, 2021
Completion
Dec 23, 2021
Results posted
Mar 16, 2023
Last update
May 18, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion